12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Company News  |  Other News

Tengion renal, cancer, gene/cell therapy news

Tengion said in its 2Q12 earnings that it expects to only have enough cash to fund its operations through Aug. 31 and therefore intends to pursue additional sources of capital. If Tengion cannot obtain additional financing the company will not be...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >